[go: up one dir, main page]

BR0208685A - Terapia de imunização à base de peptìdio para tratamento de arteriosclerose e desenvolvimento de ensaio à base de peptìdio para determinação de respostas imunes contra lipoproteìna oxidada de baixa densidade - Google Patents

Terapia de imunização à base de peptìdio para tratamento de arteriosclerose e desenvolvimento de ensaio à base de peptìdio para determinação de respostas imunes contra lipoproteìna oxidada de baixa densidade

Info

Publication number
BR0208685A
BR0208685A BR0208685-9A BR0208685A BR0208685A BR 0208685 A BR0208685 A BR 0208685A BR 0208685 A BR0208685 A BR 0208685A BR 0208685 A BR0208685 A BR 0208685A
Authority
BR
Brazil
Prior art keywords
peptide
development
determination
immunization therapy
immune responses
Prior art date
Application number
BR0208685-9A
Other languages
English (en)
Inventor
Jan Nilsson
Prediman Shah
Original Assignee
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Forskarpatent I Syd Ab filed Critical Forskarpatent I Syd Ab
Publication of BR0208685A publication Critical patent/BR0208685A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"'TERAPIA DE IMUNIZAçãO à BASE DE PEPTìDIO PARA TRATAMENTO DE ARTERIOSCLEROSE E DESENVOLVIMENTO DE ENSAIO à BASE DE PEPTìDIO PARA DETERMINAçãO DE RESPOSTAS IMUNES CONTRA LIPOPROTEìNA OXIDADA DE BAIXA DENSIDADE". A presente invenção se refere a fragmentos de apoliproteína B, em particular a peptídios definidos dos mesmos, para imunização ou tratamento terapêutico de mamíferos, incluindo seres humanos, contra doenças cardiovasculares isquêmicas, assim como para diagnosticar a presença ou ausência de anticorpos correlacionados ao aumento ou redução de risco de desenvolvimento de doenças cardiovasculares isquêmicas, usando um ou mais dos peptídios em um ensaio ELISA (Enzyme Linked Immuno Sorbent Assay).
BR0208685-9A 2001-04-05 2002-04-05 Terapia de imunização à base de peptìdio para tratamento de arteriosclerose e desenvolvimento de ensaio à base de peptìdio para determinação de respostas imunes contra lipoproteìna oxidada de baixa densidade BR0208685A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PCT/SE2002/000679 WO2002080954A1 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Publications (1)

Publication Number Publication Date
BR0208685A true BR0208685A (pt) 2004-03-30

Family

ID=26655437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208685-9A BR0208685A (pt) 2001-04-05 2002-04-05 Terapia de imunização à base de peptìdio para tratamento de arteriosclerose e desenvolvimento de ensaio à base de peptìdio para determinação de respostas imunes contra lipoproteìna oxidada de baixa densidade

Country Status (18)

Country Link
EP (42) EP2289935A1 (pt)
JP (6) JP2004529143A (pt)
CN (4) CN101486766A (pt)
AT (2) ATE510851T1 (pt)
AU (1) AU2002246484B8 (pt)
BR (1) BR0208685A (pt)
CA (3) CA2606839C (pt)
CY (1) CY1108817T1 (pt)
DE (1) DE60230029D1 (pt)
DK (3) DK1383526T3 (pt)
EE (2) EE200700052A (pt)
ES (2) ES2317999T3 (pt)
IL (4) IL158285A0 (pt)
PL (4) PL400308A1 (pt)
PT (1) PT1383526E (pt)
RU (1) RU2296582C2 (pt)
SE (1) SE0103754L (pt)
WO (1) WO2002080954A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
EP1438060B1 (en) 2001-09-28 2015-11-11 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) * 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
JP2007531537A (ja) 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
US8012483B2 (en) * 2004-04-15 2011-09-06 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
EP1676602A1 (en) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
EP2115466A4 (en) * 2006-12-22 2010-07-28 Abbott Lab HEART CIRCUIT AUTOIMMUNE DISEASE TEST GROUP AND METHOD FOR USE THEREOF
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
NZ579402A (en) 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
EP2538221A3 (en) * 2007-11-05 2013-04-24 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102099470B (zh) * 2008-08-15 2014-11-12 藤仓化成株式会社 用于诊断动脉硬化的多肽标记、用该标记等检测动脉硬化的方法以及用于诊断动脉硬化的试剂盒
CA2780753A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) * 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
WO2012024309A2 (en) 2010-08-18 2012-02-23 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
RU2013126626A (ru) * 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения гипертензий
CN103561760A (zh) * 2010-11-12 2014-02-05 赛达斯西奈医疗中心 包含apob100的免疫原性片段的免疫调节组合物、方法和系统
US9205139B2 (en) 2010-11-12 2015-12-08 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
RS58986B1 (sr) 2011-08-09 2019-08-30 Athera Biotechnologies Ab Nova antitela specifična za fosforilholin
EP2741770A4 (en) 2011-08-09 2014-12-31 Athera Biotechnologies Ab ANTIBODY BINDING TO PHOSPHORYLCHOLIN (PC) AND / OR PC CONJUGATES
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
MX364626B (es) * 2012-11-06 2019-05-03 Les Hopitaux Univ De Geneve Péptidos miméticos.
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
US11130798B2 (en) 2015-05-19 2021-09-28 La Jolla Institute For Allergy And Immunology Human APOB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
CA3129373A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis
AU2019279883B2 (en) 2018-05-29 2025-05-22 Abcentra, Llc Compositions and methods for treatment of psoriasis
CN115025210B (zh) * 2021-03-05 2025-09-05 香港中文大学 减少动脉粥样硬化进展的肽疫苗组合物和药物制剂
CN115025211A (zh) * 2021-11-02 2022-09-09 南京理工大学 用于动脉粥样硬化治疗的纳米疫苗及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (en) * 1992-03-06 1993-09-16 Abbott Laboratories Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
US6309844B1 (en) * 1997-10-15 2001-10-30 Fujirebio Inc. Anti-apo-B-48 monoclonal antibody, hybridoma producing the same, and method for measuring apo-B-48 using the same
EP1062512A4 (en) * 1998-03-10 2001-12-12 Univ California METHODS AND TOOLS USED TO IDENTIFY COMPOUNDS THAT MODULATE ATHEROSCLEROSIS BY ALTERATION OF THE LDL-PROTEOGLYCANE BINDING
WO2000002920A1 (en) * 1998-07-13 2000-01-20 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
CA2389849A1 (en) * 1999-10-26 2001-05-10 Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
WO2001057251A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
HUP0300099A3 (en) * 2000-03-03 2004-10-28 Smithkline Beecham Biolog Vaccine for the treatment of artherosclerosis
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
WO2002048388A2 (en) * 2000-10-25 2002-06-20 Vincent Agnello Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
WO2002042426A2 (en) * 2000-11-10 2002-05-30 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
BR0209572A (pt) * 2001-05-15 2004-07-13 Japan Immunores Lab Co Ltd Peptìdeo reativo com lipoproteìna de alta densidade
EP1469887A4 (en) * 2001-07-20 2006-01-11 Eidgenoess Tech Hochschule COMPOSITIONS AND METHODS FOR THE USE OF BIOACTIVE AGENTS DERIVED FROM SULFATE AND SULFONIC ACIDS

Also Published As

Publication number Publication date
EP2006301A1 (en) 2008-12-24
EP2289919A1 (en) 2011-03-02
EP1918300A3 (en) 2009-06-17
CY1108817T1 (el) 2014-04-09
ATE415423T1 (de) 2008-12-15
EP2289933A1 (en) 2011-03-02
DE60230029D1 (de) 2009-01-08
RU2003132443A (ru) 2005-02-27
CN1505525A (zh) 2004-06-16
EP2289915A1 (en) 2011-03-02
CN1505525B (zh) 2012-11-07
EP2295461A1 (en) 2011-03-16
CA2827167A1 (en) 2002-10-17
WO2002080954A1 (en) 2002-10-17
SE0103754D0 (sv) 2001-11-09
EP2147680A3 (en) 2010-04-14
ES2317999T3 (es) 2009-05-01
CA2606839A1 (en) 2002-10-17
EP2289916A1 (en) 2011-03-02
EP2289929A1 (en) 2011-03-02
EP2295460B1 (en) 2015-06-03
EP2295464B1 (en) 2015-06-03
EP2289928A1 (en) 2011-03-02
EP2295460A1 (en) 2011-03-16
EP2289935A1 (en) 2011-03-02
EP2295458A1 (en) 2011-03-16
JP2009191078A (ja) 2009-08-27
DK2006301T3 (da) 2011-09-12
EP2147680A2 (en) 2010-01-27
IL195356A0 (en) 2009-08-03
EP1383526A1 (en) 2004-01-28
EP2147929A2 (en) 2010-01-27
EP2289926A1 (en) 2011-03-02
PL217858B1 (pl) 2014-08-29
EP2289931A1 (en) 2011-03-02
EP2289923A1 (en) 2011-03-02
CN101486766A (zh) 2009-07-22
EP2147928A2 (en) 2010-01-27
CN101284874B (zh) 2012-10-03
JP5613890B2 (ja) 2014-10-29
PL400308A1 (pl) 2012-12-17
AU2002246484B8 (en) 2007-06-14
IL158285A0 (en) 2004-05-12
EP2289927A1 (en) 2011-03-02
EP2289922A1 (en) 2011-03-02
EP2006301B1 (en) 2011-05-25
EP2305707A1 (en) 2011-04-06
DK1383526T3 (da) 2009-03-30
EP2295459A1 (en) 2011-03-16
PT1383526E (pt) 2009-02-27
ES2546293T3 (es) 2015-09-22
EP2289925A1 (en) 2011-03-02
PL215401B1 (pl) 2013-12-31
IL158285A (en) 2009-12-24
EP2295462A1 (en) 2011-03-16
JP5270456B2 (ja) 2013-08-21
EP2147930A2 (en) 2010-01-27
JP5300819B2 (ja) 2013-09-25
ATE510851T1 (de) 2011-06-15
EP2289917A1 (en) 2011-03-02
EE200700052A (et) 2008-08-15
EP2295464A1 (en) 2011-03-16
EP2147928A3 (en) 2010-04-14
EP2289930A1 (en) 2011-03-02
EP2289918A1 (en) 2011-03-02
EP2289924A1 (en) 2011-03-02
RU2296582C2 (ru) 2007-04-10
CN103122031A (zh) 2013-05-29
EP2289913A1 (en) 2011-03-02
EP2289912A1 (en) 2011-03-02
EP2147929A3 (en) 2010-04-14
EP2289914A1 (en) 2011-03-02
JP2008169215A (ja) 2008-07-24
JP5300820B2 (ja) 2013-09-25
CA2443223C (en) 2013-11-26
EP2289921A1 (en) 2011-03-02
PL367301A1 (en) 2005-02-21
EP2147930A3 (en) 2010-04-14
EP2305708A1 (en) 2011-04-06
JP2011063598A (ja) 2011-03-31
EP1918300A2 (en) 2008-05-07
EE200300487A (et) 2004-02-16
CA2443223A1 (en) 2002-10-17
EP2289920A1 (en) 2011-03-02
EP2289934B1 (en) 2013-11-13
JP2004529143A (ja) 2004-09-24
AU2002246484A1 (en) 2002-10-21
DK2295464T3 (en) 2015-08-17
CN103122031B (zh) 2015-07-22
CA2606839C (en) 2015-06-09
AU2002246484B2 (en) 2007-04-19
EP2289934A1 (en) 2011-03-02
EP2305706A1 (en) 2011-04-06
EP1383526B1 (en) 2008-11-26
JP2011068654A (ja) 2011-04-07
EP2295463A1 (en) 2011-03-16
EP2295457A1 (en) 2011-03-16
IL188286A0 (en) 2008-03-20
EP2289932A1 (en) 2011-03-02
JP2013144687A (ja) 2013-07-25
SE0103754L (sv) 2002-10-06
CN101284874A (zh) 2008-10-15

Similar Documents

Publication Publication Date Title
BR0208685A (pt) Terapia de imunização à base de peptìdio para tratamento de arteriosclerose e desenvolvimento de ensaio à base de peptìdio para determinação de respostas imunes contra lipoproteìna oxidada de baixa densidade
Roivainen et al. Infections, inflammation, and the risk of coronary heart disease
Duryee et al. Malondialdehyde–acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis
ECSP024409A (es) Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
AT500379B8 (de) Tau-proteine
Korponay–Szabó et al. Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease–specific autoantibodies
Tian et al. Effect of Rothia mucilaginosa enzymes on gliadin (gluten) structure, deamidation, and immunogenic epitopes relevant to celiac disease
Nakamura et al. Tissue transglutaminase generates deamidated epitopes on gluten, increasing reactivity with hydrolyzed wheat protein–sensitized IgE
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
Wen et al. A novel extraction method for peanut allergenic proteins in chocolate and their detection by a liposome-based lateral flow assay
Fritsché et al. IgE-mediated rat mast cell triggering with tryptic and synthetic peptides of bovine β-lactoglobulin
JP4374248B2 (ja) アテローム性動脈硬化症の治療用の手段
BRPI0216033B8 (pt) "terapia de imunização à base de peptídio para tratamento de arteriosclerose"
Autrup et al. Evidence for human antibodies that recognize an aflatoxin epitope in groups with high and low exposure to aflatoxins
EP1495056A4 (en) ANTIBODY DISULFIDISOMERS, THEIR USE AND METHOD FOR THEIR ANALYSIS
Wedege et al. IgG antibody levels to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements
Datta et al. Evaluation of anti-gal enzyme-linked immunosorbent assay for the diagnosis of Indian post-kala-azar dermal leishmaniasis
Kambayashi et al. Preparation and characterization of a polyclonal antibody against brominated protein
Ikegawa et al. Immunoprecipitation and MALDI-MS identification of lithocholic acid-tagged proteins in liver of bile duct-ligated rats
Kim et al. Secretome analysis of host cells infected with Toxoplasma gondii after treatment of human epidermal growth factor receptor 2/4 inhibitors
Schwenke et al. α-tocopherol and probucol reduce autoantibody titer to MDA-LDL in hypercholesterolemic rabbits
Musa Modifications influencing Widal test reactivity in a novel microplate assay
Maso et al. Immunopathological changes after multiple spider bites
Levy et al. 12 Obstructive sleep apnea in children with chronic rhinitis
SE0104354D0 (sv) Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based ELISA for determination of immune responses against oxidized low-density lipoprotein

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: CARDIOVAX, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL